Biogen (BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia between the ages of 2 to less than16. Both non-ambulatory and ambulatory participants may qualify for the study. Currently, omaveloxolone is commercialized under the brand name SKYCLARYS in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- H.C. Wainwright sees potential competition for Sage from Biogen
- Biogen’s Strategic Diversification and Promising Pipeline Drive Buy Rating
- Sage Therapeutics price target raised to $8.50 from $8 at Canaccord
- Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets